Profile and Frequency of Mutations Conferring Drug-Resistant Tuberculosis in the Central, Southeastern and Eastern Ethiopia

References

• World Health Organization. Global Tuberculosis Report 2021. World Health Organization; 2021. Available from: https://apps.who.int/iris/handle/10665/346387. Accessed May 18, 2022.
   Google Scholar
• Federal Ministry of Health of Ethiopia. Guidelines on Programmatic Management of Drug Resistance TB in Ethiopia. 2nd ed. Federal Ministry of Health of Ethiopia; 2014.
   Google Scholar
• World Health Organization. Global Tuberculosis Report 2020. World Health Organization; 2020. Available from: https://apps.who.int/iris/handle/10665/336069. Accessed November 19, 2022.
   Google Scholar
• Jacobson KR, Theron D, Kendall EA, et al. Implementation of GENOTYPE MTBDRplus reduces time to multidrug-resistant tuberculosis therapy initiation in South Africa. Clin Infect Dis. 2013;56(4):503–508. doi:10.1093/cid/cis920
   PubMed Web of Science ®Google Scholar
• World Health Organization. The Use of Molecular Line Probe Assay for the Detection of Resistance to Isoniazid and Rifampicin: Policy Update. World Health Organization; 2016. Available from: https://apps.who.int/iris/handle/10665/250586. Accessed November 22, 2022.
   Google Scholar
• World Health Organization. Line Probe Assays for Detection of Drug-Resistant Tuberculosis: Interpretation and Reporting Manual for Laboratory Staff and Clinicians. World Health Organization; 2022. Available from: https://apps.who.int/iris/handle/10665/354240. Accessed November 22, 2022.
   Google Scholar
• Li G, Guo Q, Liu H, et al. Detection of resistance to fluoroquinolones and second-line injectable drugs among mycobacterium tuberculosis by a reverse dot blot hybridization assay. Infect Drug Resist. 2020;13:4091–4104. doi:10.2147/IDR.S270209
   PubMed Web of Science ®Google Scholar
• World Health Organization. The Use of Molecular Line Probe Assays for the Detection of Resistance to Second-Line Anti-Tuberculosis Drugs: Policy Guidance. World Health Organization; 2016. Available from: https://apps.who.int/iris/handle/10665/246131. Accessed November 22, 2022.
   Google Scholar
• Federal Ministry of Health of Ethiopia. Guideline for the program and clinical management of drug resistant tuberculosis first; 2011.
   Google Scholar
• World Health Organization. Catalogue of Mutations in Mycobacterium Tuberculosis Complex and Their Association with Drug Resistance. World Health Organization; 2021. Available from: https://apps.who.int/iris/handle/10665/341981. Accessed November 19, 2022.
   Google Scholar
• Campbell PJ, Morlock GP, Sikes RD, et al. Molecular detection of mutations associated with first- and second-line drug resistance compared with conventional drug susceptibility testing of Mycobacterium tuberculosis. Antimicrob Agents Chemother. 2011;55(5):2032–2041. doi:10.1128/AAC.01550-10
   PubMed Web of Science ®Google Scholar
• Seifert M, Catanzaro D, Catanzaro A, Rodwell TC. Genetic mutations associated with isoniazid resistance in Mycobacterium tuberculosis: a systematic review. PLoS One. 2015;10(3):e0119628. doi:10.1371/journal.pone.0119628
   PubMed Web of Science ®Google Scholar
• Shen GH, Chen CH, Hung CH, et al. Combining the Capilia TB assay with smear morphology for the identification of Mycobacterium tuberculosis complex. Int J Tuberc Lung Dis. 2009;13(3):371–376.
   PubMed Web of Science ®Google Scholar
• HAIN Lifescience. GenoType MTBDRplus v.2.0, Molecular genetic assay for identification of the M. tuberculosis complex and its resistance to rifampicin and isoniazid from clinical specimens and cultivated samples; 2015.
   Google Scholar
• HAIN Lifescience. GenoType MTBDRsl VER 2.0, Molecular Genetic Assay for Identification of the M. tuberculosis Complex and its Resistance to Fluoroquinolones and Aminoglycosides/Cyclic Peptides from Sputum Specimens or Cultivated Samples; 2017.
   Google Scholar
• Hirani N, Joshi A, Anand S, et al. Detection of a novel mutation in the rpoB gene in a multidrug resistant Mycobacterium tuberculosis isolate using whole genome next generation sequencing. J Glob Antimicrob Resist. 2020;22:270–274. doi:10.1016/j.jgar.2020.03.004
   PubMed Web of Science ®Google Scholar
• Brhane M, Kebede A, Petros Y. Molecular detection of multidrug-resistant tuberculosis among smear-positive pulmonary tuberculosis patients in Jigjiga town, Ethiopia. Infect Drug Resist. 2017;10:75–83. doi:10.2147/IDR.S127903
   PubMed Web of Science ®Google Scholar
• Tessema B, Beer J, Emmrich F, Sack U, Rodloff AC. Analysis of gene mutations associated with isoniazid, rifampicin and ethambutol resistance among Mycobacterium tuberculosis isolates from Ethiopia. BMC Infect Dis. 2012;12(1):37. doi:10.1186/1471-2334-12-37
   PubMedGoogle Scholar
• Reta MA, Alemnew B, Abate BB, Fourie PB. Prevalence of drug resistance-conferring mutations associated with isoniazid- and rifampicin-resistant Mycobacterium tuberculosis in Ethiopia: a systematic review and meta-analysis. J Glob Antimicrob Resist. 2021;26:207–218. doi:10.1016/j.jgar.2021.06.009
   PubMed Web of Science ®Google Scholar
• Damena D, Tolosa S, Hailemariam M, et al. Genetic diversity and drug susceptibility profiles of Mycobacterium tuberculosis obtained from Saint Peter’s TB specialized Hospital, Ethiopia. PLoS One. 2019;14(6):e0218545. doi:10.1371/journal.pone.0218545
   PubMed Web of Science ®Google Scholar
• Tadesse M, Abebe G, Bekele A, et al. The predominance of Ethiopian specific Mycobacterium tuberculosis families and minimal contribution of Mycobacterium bovis in tuberculous lymphadenitis patients in Southwest Ethiopia. Infect Genet Evol. 2017;55:251–259. doi:10.1016/j.meegid.2017.09.016
   PubMed Web of Science ®Google Scholar
• Welekidan LN, Skjerve E, Dejene TA, et al. Frequency and patterns of first- and second-line drug resistance-conferring mutations in Mycobacterium tuberculosis isolated from pulmonary tuberculosis patients in a cross-sectional study in Tigray Region, Ethiopia. J Glob Antimicrob Resist. 2021;24:6–13. doi:10.1016/j.jgar.2020.11.017
   PubMed Web of Science ®Google Scholar
• Elbir H, Ibrahim NY. Frequency of mutations in the rpoB gene of multidrug-resistant Mycobacterium tuberculosis clinical isolates from Sudan. J Infect Dev Ctries. 2014;8(06):796–798. doi:10.3855/jidc.4496
   PubMedGoogle Scholar
• Maurya A, Singh A, Kant S, et al. Use of GenoType® MTBDRplus assay to assess drug resistance and mutation patterns of multidrug-resistant tuberculosis isolates in northern India. Indian J Med Microbiol. 2013;31(3):230–236. doi:10.4103/0255-0857.115625
   PubMed Web of Science ®Google Scholar
• Hamed Z, Mohajeri P, Farahani A, et al. The frequency of point mutations associated with resistance to isoniazid and rifampin among clinical isolates of multidrug-resistant Mycobacterium tuberculosis in the west of Iran. Gene Rep. 2021;22:100981. doi:10.1016/j.genrep.2020.100981
   Web of Science ®Google Scholar
• Farooqi JQ, Khan E, Alam SMZ, Ali A, Hasan Z. Line probe assay for detection of rifampicin and isoniazid resistant tuberculosis in Pakistan. J Pak Med Assoc. 2012;62:767.
   PubMed Web of Science ®Google Scholar
• Jian J, Yang X, Yang J, Chen L. Evaluation of the GenoType MTBDRplus and MTBDRsl for the detection of drug-resistant Mycobacterium tuberculosis on isolates from Beijing, China. Infect Drug Resist. 2018;11:1627–1634. doi:10.2147/IDR.S176609
   PubMed Web of Science ®Google Scholar
• Alvarez-Uria G, Reddy R. Differences in rpoB, katG and inhA mutations between new and previously treated tuberculosis cases using the GenoType MTBDR plus assay. Infect Genet Evol. 2018;59:48–50. doi:10.1016/j.meegid.2018.01.022
   PubMed Web of Science ®Google Scholar
• Rando-Segura A, Aznar ML, Moreno MM, et al. Molecular characterization of rpoB gene mutations in isolates from tuberculosis patients in Cubal, Republic of Angola. BMC Infect Dis. 2021;21. doi:10.1186/s12879-021-06763-8
   PubMed Web of Science ®Google Scholar
• Franco-Sotomayor G, Garzon-Chavez D, Leon-Benitez M, de Waard JH, Garcia-Bereguiain MA, First A. Insight into the katG and rpoB gene mutations of multidrug-resistant Mycobacterium tuberculosis strains from Ecuador. Microb Drug Resist. 2019;25(4):524–527. doi:10.1089/mdr.2018.0203
   PubMed Web of Science ®Google Scholar
• Abate D, Tedla Y, Meressa D, Ameni G. Isoniazid and rifampicin resistance mutations and their effect on second-line anti-tuberculosis treatment. Int J Tuberc Lung Dis. 2014;18(8):946–951. doi:10.5588/ijtld.13.0926
   PubMed Web of Science ®Google Scholar
• Tadesse M, Aragaw D, Dimah B, et al. Drug resistance-conferring mutations in Mycobacterium tuberculosis from pulmonary tuberculosis patients in Southwest Ethiopia. Int J Mycobacteriol. 2016;5(2):185–191. doi:10.1016/j.ijmyco.2016.02.009
   PubMedGoogle Scholar
• Seifert M, Georghiou SB, Catanzaro D, et al. MTBDR plus and MTBDR sl assays: absence of wild-type probe hybridization and implications for detection of drug-resistant tuberculosis. J Clin Microbiol. 2016;54(4):912–918. doi:10.1128/JCM.02505-15
   PubMed Web of Science ®Google Scholar
• Zhang Y, Yew WW. Mechanisms of drug resistance in Mycobacterium tuberculosis. Int J Tuberc Lung Dis off J Int Union Tuberc Lung Dis. 2009;13(11):1320–1330.
   PubMed Web of Science ®Google Scholar
• Bostanabad S, Titov L, Bahrmand A, Nojoumi S. Detection of mutation in isoniazid-resistant mycobacterium tuberculosis isolates from tuberculosis patients in Belarus. Indian J Med Microbiol. 2008;26(2):143–147. doi:10.1016/S0255-0857(21)01930-7
   PubMed Web of Science ®Google Scholar
• van Soolingen D, de Haas PEW, van Doorn HR, Kuijper E, Rinder H, Borgdorff MW. Mutations at amino acid position 315 of the katG Gene are associated with high‐level resistance to isoniazid, other drug resistance, and successful transmission of Mycobacterium tuberculosis in The Netherlands. J Infect Dis. 2000;182(6):1788–1790. doi:10.1086/317598
   PubMed Web of Science ®Google Scholar
• Biadglegne F, Tessema B, Rodloff AC, Sack U. Magnitude of gene mutations conferring drug resistance in Mycobacterium tuberculosis isolates from lymph node aspirates in Ethiopia. Int J Med Sci. 2013;10(11):1589–1594. doi:10.7150/ijms.6806
   PubMed Web of Science ®Google Scholar
• Tilahun M, Shimelis E, Wogayehu T, et al. Molecular detection of multidrug resistance pattern and associated gene mutations in M. tuberculosis isolates from newly diagnosed pulmonary tuberculosis patients in Addis Ababa, Ethiopia. PLoS One. 2020;15(8):e0236054. doi:10.1371/journal.pone.0236054
   PubMed Web of Science ®Google Scholar
• Alelign A, Petros B, Ameni G. Smear positive tuberculosis and genetic diversity of M. tuberculosis isolates in individuals visiting health facilities in South Gondar Zone, northwest Ethiopia. PLoS One. 2019;14(8):e0216437. doi:10.1371/journal.pone.0216437
   PubMed Web of Science ®Google Scholar
• Diriba G, Alemu A, Tola HH, et al. Pre-extensively drug-resistant tuberculosis among multidrug-resistant tuberculosis patients in Ethiopia: a laboratory-based surveillance study. IJID Reg. 2022;5:39–43. doi:10.1016/j.ijregi.2022.08.012
   PubMedGoogle Scholar
• Agonafir M, Lemma E, Wolde-Meskel D, et al. Phenotypic and genotypic analysis of multidrug-resistant tuberculosis in Ethiopia. Int J Tuberc Lung Dis. 2010;14(10):1259–1265.
   PubMed Web of Science ®Google Scholar
• Shibabaw A, Gelaw B, Gebreyes W, Robinson R, Wang SH, Tessema B. The burden of pre-extensively and extensively drug-resistant tuberculosis among MDR-TB patients in the Amhara region, Ethiopia. PLoS One. 2020;15(2):e0229040. doi:10.1371/journal.pone.0229040
   PubMed Web of Science ®Google Scholar
• Avalos E, Catanzaro D, Catanzaro A, et al. Frequency and geographic distribution of gyrA and gyrB mutations associated with fluoroquinolone resistance in clinical Mycobacterium tuberculosis isolates: a systematic review. PLoS One. 2015;10(3):e0120470. doi:10.1371/journal.pone.0120470
   PubMed Web of Science ®Google Scholar
• Chaoui I, Oudghiri A, El Mzibri M. Characterization of gyrA and gyrB mutations associated with fluoroquinolone resistance in Mycobacterium tuberculosis isolates from Morocco. J Glob Antimicrob Resist. 2018;12:171–174. doi:10.1016/j.jgar.2017.10.003
   PubMed Web of Science ®Google Scholar
• Jou R, Lee WT, Kulagina EV, et al. Redefining MDR-TB: comparison of Mycobacterium tuberculosis clinical isolates from Russia and Taiwan. Infect Genet Evol. 2019;72:141–146. doi:10.1016/j.meegid.2018.12.031
   PubMed Web of Science ®Google Scholar
• Singh PK, Singh U, Jain A. Emergence of specific gyr A mutations associated high-level fluoroquinolone-resistant Mycobacterium tuberculosis among multidrug-resistant tuberculosis cases in North India. Microb Drug Resist. 2021;27(5):647–651. doi:10.1089/mdr.2020.0240
   PubMed Web of Science ®Google Scholar
• Kabir S, Tahir Z, Mukhtar N, Sohail M, Saqalein M, Rehman A. Fluoroquinolone resistance and mutational profile of gyrA in pulmonary MDR tuberculosis patients. BMC Pulm Med. 2020;20(1):138. doi:10.1186/s12890-020-1172-4
   PubMed Web of Science ®Google Scholar
• Jnawali HN, Hwang SC, Park YK, et al. Characterization of mutations in multi- and extensive drug resistance among strains of Mycobacterium tuberculosis clinical isolates in Republic of Korea. Diagn Microbiol Infect Dis. 2013;76(2):187–196. doi:10.1016/j.diagmicrobio.2013.02.035
   PubMed Web of Science ®Google Scholar
• Ajbani K, Nikam C, Kazi M, et al. Evaluation of genotype MTBDRsl assay to detect drug resistance associated with fluoroquinolones, aminoglycosides and ethambutol on clinical sediments. PLoS One. 2012;7(11):e49433. doi:10.1371/journal.pone.0049433
   PubMed Web of Science ®Google Scholar
• Singhal R, Reynolds PR, Marola JL, et al. Sequence analysis of fluoroquinolone resistance-associated genes gyrA and gyrB in clinical Mycobacterium tuberculosis isolates from patients suspected of having multidrug-resistant tuberculosis in New Delhi, India. J Clin Microbiol. 2016;54(9):2298–2305. doi:10.1128/JCM.00670-16
   PubMed Web of Science ®Google Scholar
• Ford C, Yusim K, Ioerger T, et al. Mycobacterium tuberculosis – heterogeneity revealed through whole genome sequencing. Tuberculosis. 2012;92(3):194–201. doi:10.1016/j.tube.2011.11.003
   PubMed Web of Science ®Google Scholar
• Abakur EHA, Alnour TMS, Abuduhier F, Albalawi FMA, Alfifi KAS. Emergence of heteroresistance Mycobacterium tuberculosis in Saudi Arabia. Infect Disord Drug Targets. 2020;20(4):491–494. doi:10.2174/1871526519666190326141550
   PubMedGoogle Scholar
• Liang B, Tan Y, Li Z, et al. Highly sensitive detection of isoniazid heteroresistance in Mycobacterium tuberculosis by DeepMelt assay. J Clin Microbiol. 2018;56(2):e01239. doi:10.1128/JCM.01239-17
   PubMed Web of Science ®Google Scholar
• Georghiou SB, Magana M, Garfein RS, Catanzaro DG, Catanzaro A, Rodwell TC. Evaluation of genetic mutations associated with Mycobacterium tuberculosis resistance to Amikacin, Kanamycin and Capreomycin: a systematic review. PLoS One. 2012;7(3):12. doi:10.1371/journal.pone.0033275
   Web of Science ®Google Scholar
• World Health Organization. Meeting Report of the WHO Expert Consultation on the Definition of Extensively Drug-Resistant Tuberculosis. World Health Organization; 2021. Available from: https://apps.who.int/iris/handle/10665/338776. Accessed April 1, 2022.
   Google Scholar